Innovent Biologics begins patient dosing in phase 3 study of IBI354 for platinum-resistant ovarian cancer: San Francisco Tuesday, March 25, 2025, 18:00 Hrs [IST] Innovent Biologic ...

OS Therapies ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced that OST-HER2 is featured in the upcoming ...

As AbbVie accuses Genmab of unlawfully using proprietary ADC technology, find out about their collaboration and the dispute ...

ADC Therapeutics' primary focus is on the CD19-targeted antibody-drug conjugate Zynlonta. Read why ADCT stock is rated as a ...

Panelists discuss how the current treatment landscape for patients with late-line relapsed/refractory multiple myeloma (RRMM) involves novel approaches such as bispecific antibodies, CAR-T cell ...

The company said initial efficacy results from a Phase I trial did not provide a competitive benefit-risk profile in CLDN18.2-positive gastric and gastroesophageal cancer.

AbbVie claims that Genmab divulged key trade secrets to support the development of ProfoundBio’s investigational ...

Companies from these countries collectively account for 19 out of 28 assets worldwide. South Korea and China are leading in ...

Glucagon-like peptide-1 (GLP-1) receptor agonists are peptide-based therapeutics for treating diabetes and for weight loss.

What drew you to pursue a career in oncology and what is it that inspires you most about working in this field?

Antibody-drug conjugates have had a tremendous impact on breast cancer care and treatment, according to Dr. Charles E. Geyer.